CVI-VZV-001 / CHA Vaccine Institute - LARVOL DELTA

Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above (clinicaltrials.gov) - P2 | N=135 | Not yet recruiting | Sponsor: CHA Vaccine Institute Co., Ltd.

New P2 trial • Herpes Zoster • Varicella Zoster

Lipo-pam™ adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses. (PubMed, NPJ Vaccines) - "Shingrix is a recombinant zoster vaccine that is currently used to prevent HZ. At present, CVI-VZV-001 is undergoing phase I clinical trials. This study suggests that CVI-VZV-001 can be a potent candidate for the HZ vaccine with high immunogenicity and safety."

Journal • Herpes Zoster • Infectious Disease • Pain • Varicella Zoster • CD4